Perils of the Pathologic Complete Response-Reference-Cited by-同舟云学术

Perils of the Pathologic Complete Response

Published:2016-11-20 Issue:33 Volume:34 Page:3959-3962
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Rose Brent S.¹,Winer Eric P.¹,Mamon Harvey J.¹

Affiliation:

1. Brent S. Rose, Harvard Radiation Oncology Program, Boston, MA; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; and Harvey J. Mamon, Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, MA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2016.68.1718

Reference41 articles.

1. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

2. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

3. Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

4. Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

5. Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. “Heterogeneity of treatment effect on patients’ long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer.”;The Breast;2024-02

2. Validity of Using Pathological Response as a Surrogate for Overall Survival in Neoadjuvant Studies for Esophageal Cancer: A Systematic Review and Meta-analysis;Annals of Surgical Oncology;2023-07-03

3. Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial;Cancers;2023-03-13

4. Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer;JAMA Oncology;2022-11-01

5. Analysis of delay in adjuvant chemotherapy in locally advanced rectal cancer;Techniques in Coloproctology;2022-08-30